Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs lepirudin in heparin-induced thrombocytopenia
2007-000564-25Phase 3Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- May 2007
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of fondaparinux and lepirudin in heparin-induced thrombocytopenia (HIT) (2 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: cumulative incidence of new clinically manifest thromboembolic complications, amputations and death. Started May 2007; status: terminated.
02
Drugs
fondaparinuxlepirudin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on 2007-000564-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000564-25.